Clinical Differences and Outcomes between Methamphetamine-Associated and Idiopathic Pulmonary Arterial Hypertension in the PHAR.
暂无分享,去创建一个
D. Glidden | N. Kolaitis | R. Benza | D. Badesch | S. Mathai | M. Simon | O. Shlobin | S. Kawut | V. A. de Jesus Perez | M. Chakinala | T. De Marco | C. Burger | R. Zamanian | J. Sager | J. Elwing | J. Singer | Jeffrey C. Robinson | M. Lammi | J. McConnell | J. Feldman | K. Presberg | J. Mcconnell | J. Robinson
[1] R. Kronmal,et al. Age-related differences in hemodynamics and functional status in pulmonary arterial hypertension: Baseline results from the Pulmonary Hypertension Association Registry. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[2] Yu Wang,et al. Methamphetamine produces cardiac damage and apoptosis by decreasing melusin. , 2019, Toxicology and applied pharmacology.
[3] P. Chan,et al. Screening Of Pulmonary Hypertension in Methamphetamine Abusers (SOPHMA): rationale and design of a multicentre, cross-sectional study , 2019, BMJ Open.
[4] G. Simonneau,et al. An overview of the 6th World Symposium on Pulmonary Hypertension , 2019, European Respiratory Journal.
[5] Paul G. Williams,et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.
[6] M. Crawford,et al. Clinical Characteristics and Outcome of Methamphetamine-Associated Pulmonary Arterial Hypertension and Dilated Cardiomyopathy. , 2018, JACC. Heart failure.
[7] Johan Duflou,et al. Prevalence and nature of cardiovascular disease in methamphetamine-related death: A national study. , 2017, Drug and alcohol dependence.
[8] M. Humbert,et al. Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study , 2017, European Respiratory Journal.
[9] G. Schuler,et al. Clinical Characteristics, Histopathological Features, and Clinical Outcome of Methamphetamine-Associated Cardiomyopathy. , 2017, JACC. Heart failure.
[10] G. Colditz,et al. Optimal design of longitudinal data analysis using generalized estimating equation models , 2017, Biometrical journal. Biometrische Zeitschrift.
[11] M. Akhgari,et al. Histopathological study of cardiac lesions in methamphetamine poisoning-related deaths , 2017, DARU Journal of Pharmaceutical Sciences.
[12] B. Westerhof,et al. The Relationship Between the Right Ventricle and its Load in Pulmonary Hypertension. , 2017, Journal of the American College of Cardiology.
[13] D. Preen,et al. Barriers to accessing methamphetamine treatment: A systematic review and meta-analysis. , 2016, Drug and alcohol dependence.
[14] M. Kesting,et al. Evaluation of methamphetamine-associated socioeconomic status and addictive behaviors, and their impact on oral health. , 2015, Addictive behaviors.
[15] R. Benza,et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. , 2015, Chest.
[16] Sanjiv J. Shah,et al. Management of Pulmonary Arterial Hypertension , 2015, Seminars in Respiratory and Critical Care Medicine.
[17] M. Humbert,et al. Drug-induced pulmonary arterial hypertension: a recent outbreak , 2013, European Respiratory Review.
[18] J. Loscalzo,et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials). , 2013, The American journal of cardiology.
[19] W. Honer,et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. , 2013, Drug and alcohol dependence.
[20] M. Humbert,et al. Pulmonary arterial hypertension: epidemiology and registries. , 2013, Journal of the American College of Cardiology.
[21] T. Ishikawa,et al. Water-restraint stress enhances methamphetamine-induced cardiotoxicity. , 2011, Chemico-biological interactions.
[22] Constantine Frangakis,et al. Multiple imputation by chained equations: what is it and how does it work? , 2011, International journal of methods in psychiatric research.
[23] Patrick Royston,et al. Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.
[24] P. Katz,et al. Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension , 2011, European Respiratory Journal.
[25] R. Mcketin,et al. Methamphetamine-related fatalities in Australia: demographics, circumstances, toxicology and major organ pathology. , 2008, Addiction.
[26] R. Rothman,et al. Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. , 2007, Chest.
[27] K. Chin,et al. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? , 2006, Chest.
[28] S. Hodge,et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives , 2002, European Respiratory Journal.
[29] T. Petty,et al. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. , 1993, Chest.